Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion – $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS outlook to $3.29 – $3.33 versus an estimate of $3.24.
Salesforce In Artificial Intelligence Era, Personal Spending Rises But Income Falls, New Inflation Data
To gain an edge, this is what you need to know today.
